CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
CRISPR Therapeutics AG
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$50.04+0.79 (+1.60%)
Close on Oct 19, 2026
- Market cap
- $4.83B
- P/E (TTM)
- –
- Dividend yield
- –
CRISPR Therapeutics AG revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Grant Revenue [Member] | $3.51M | $2.31M | $1.21M | $762.00K | $1.88M | $176.00K | – | – | 100.0% | +51.7% |
| Collaboration Revenue [Member] | $0 | $35.00M | $370.00M | $436.00K | $913.08M | $543.00K | $289.59M | $3.12M | 0.0% | -100.0% |
By region
From the segment and revenue-disaggregation notes of CRISPR Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.